HYFT
ImmunoPrecise Antibodies Ltd.
1.50$
+11.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.0% | 15.0% | -27.4% | -62.8% | -29.3% | -9.5% | -3.3% | -51.2% | -96.0% | -17.3% | -26.1% | -80.1% | |
| 0.1% | 2.2% | 1.9% | 8.4% | 20.7% | 23.2% | 20.7% | 19.5% | 32.3% | 23.4% | 20.9% | 10.3% | |
| – | – | 7.5% | 22.4% | 10.2% | 5.0% | 15.3% | 15.9% | 9.4% | 6.3% | 1.8% | 8.3% | |
| 0.0% | 3.8% | 14.5% | -3.6% | 5.3% | -7.6% | -5.7% | 3.0% | -15.9% | 9.8% | 1.1% | -13.2% | |
| 1.2% | 0.9% | 20.2% | 6.3% | 5.9% | 3.9% | 8.0% | 6.5% | 7.2% | 5.7% | 3.3% | 2.6% | |
| 0.0% | -4.3% | -6.6% | -131.8% | -20.2% | -10.8% | -13.7% | -26.9% | -9.5% | -6.4% | -3.3% | 87.1% | |
| 11.3% | 3.4% | 3.4% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -5.0% | -6.5% | -5.5% | 10.9% | -5.1% | |
| 0.0% | -4.8% | 120.4% | 180.1% | 85.6% | 1.2% | 242.2% | 14.9% | -3.0% | 4.2% | 60.7% | 0.7% | |
| -2.1% | 6.7% | 85.1% | -14.2% | 34.2% | -19.3% | 218.6% | -60.9% | -104.9% | -19.7% | 29.6% | 5.5% | |
| -3.2% | 14.1% | -47.6% | -69.1% | -35.3% | -13.4% | -11.3% | -57.7% | -103.2% | -23.0% | -29.4% | -82.7% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.